Many patients with an aggressive lymphoma will be cured with frontline therapy. However, relapsed patients cannot always be cured and die as a result of their disease. Fortunately, many trials in frontline and relapsed setting address the medical need of patients with a high risk of inferior survival. Especially immunotherapies have shown promising results and some of these therapies have already become standard of care, or will be in the near future. This paper provides a summary of the most interesting clinical trials in aggressive lymphoma, presented at the 2022 ASH meeting.
(BELG J HEMATOL 2023;14(1):4–9)